Guggenheim Capital’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.45M Buy
125,518
+31,550
+34% +$2.1M 0.05% 332
2026
Q1
$5.9M Sell
93,968
-21,520
-19% -$1.5M 0.05% 400
2025
Q4
$7.66M Buy
115,488
+1,930
+2% +$125K 0.05% 329
2025
Q3
$7.64M Buy
113,558
+2,631
+2% +$208K 0.06% 334
2025
Q2
$9.68M Buy
110,927
+19,710
+22% +$1.54M 0.08% 256
2025
Q1
$6.23M Sell
91,217
-24,500
-21% -$2M 0.06% 367
2024
Q4
$9M Sell
115,717
-30,236
-21% -$2.24M 0.07% 280
2024
Q3
$9.78M Buy
145,953
+7,018
+5% +$576K 0.07% 317
2024
Q2
$15.8M Buy
138,935
+7,988
+6% +$1.01M 0.11% 176
2024
Q1
$18.2M Sell
130,947
-6,068
-4% -$763K 0.13% 161
2023
Q4
$17M Buy
137,015
+16,995
+14% +$1.74M 0.13% 163
2023
Q3
$11.2M Buy
120,020
+8,148
+7% +$918K 0.1% 230
2023
Q2
$14.4M Sell
111,872
-4,605
-4% -$557K 0.11% 190
2023
Q1
$13.5M Buy
116,477
+11,037
+10% +$1.24M 0.11% 198
2022
Q4
$11.9M Sell
105,440
-28,563
-21% -$3.14M 0.1% 236
2022
Q3
$10.8M Sell
134,003
-57,013
-30% -$4.83M 0.1% 248
2022
Q2
$14.2M Sell
191,016
-8,564
-4% -$782K 0.11% 220
2022
Q1
$25.5M Sell
199,580
-74,044
-27% -$8.1M 0.15% 142
2021
Q4
$36.7M Buy
273,624
+36,016
+15% +$5.18M 0.19% 100
2021
Q3
$32.5M Sell
237,608
-22,864
-9% -$2.88M 0.2% 96
2021
Q2
$27.8M Buy
260,472
+39,984
+18% +$3.84M 0.16% 116
2021
Q1
$19.8M Sell
220,488
-49,128
-18% -$4.61M 0.13% 166
2020
Q4
$24.9M Buy
269,616
+39,336
+17% +$3.51M 0.16% 105
2020
Q3
$23.7M Sell
230,280
-80
-0% -$8.36K 0.17% 102
2020
Q2
$23.3M Buy
230,360
+112,972
+96% +$10.1M 0.18% 105
2020
Q1
$7.9M Sell
117,388
-62,012
-35% -$3.86M 0.08% 275
2019
Q4
$9.81M Buy
179,400
+23,076
+15% +$1.09M 0.07% 329
2019
Q3
$5.83M Sell
156,324
-69,236
-31% -$2.69M 0.05% 519
2019
Q2
$8.45M Sell
225,560
-6,148
-3% -$193K 0.07% 349
2019
Q1
$6.9M Sell
231,708
-424
-0.2% -$14.9K 0.06% 447
2018
Q4
$6.95M Buy
232,132
+4,396
+2% +$139K 0.06% 398
2018
Q3
$8.14M Buy
227,736
+12,980
+6% +$402K 0.05% 449
2018
Q2
$5.1M Buy
214,756
+11,152
+5% +$236K 0.03% 709
2018
Q1
$3.77M Buy
203,604
+43,320
+27% +$641K 0.01% 1172
2017
Q4
$2.3M Buy
160,284
+12,344
+8% +$160K 0.01% 1562
2017
Q3
$1.81M Buy
147,940
+52,620
+55% +$930K ﹤0.01% 1742
2017
Q2
$1.74M Buy
95,320
+23,908
+33% +$442K ﹤0.01% 1729
2017
Q1
$1.51M Buy
71,412
+11,476
+19% +$224K ﹤0.01% 1850
2016
Q4
$894K Sell
59,936
-140
-0.2% -$2.48K ﹤0.01% 2201
2016
Q3
$1.32M Buy
60,076
+11,484
+24% +$256K ﹤0.01% 1905
2016
Q2
$964K Sell
48,592
-408
-0.8% -$6.95K ﹤0.01% 2072
2016
Q1
$832K Buy
49,000
+272
+0.6% +$4.54K ﹤0.01% 2161
2015
Q4
$998K Sell
48,728
-6,824
-12% -$142K ﹤0.01% 2107
2015
Q3
$1.19M Sell
55,552
-39,476
-42% -$881K ﹤0.01% 1983
2015
Q2
$1.9M Sell
95,028
-4,516
-5% -$79.3K ﹤0.01% 1823
2015
Q1
$1.55M Buy
99,544
+3,044
+3% +$46K ﹤0.01% 1983
2014
Q4
$1.33M Buy
96,500
+18,956
+24% +$232K ﹤0.01% 2036
2014
Q3
$775K Buy
77,544
+544
+0.7% +$5.56K ﹤0.01% 2359
2014
Q2
$764K Sell
77,000
-3,864
-5% -$34.2K ﹤0.01% 2408
2014
Q1
$836K Buy
80,864
+57,880
+252% +$598K ﹤0.01% 2361
2013
Q4
$203K Buy
+22,984
New +$182K ﹤0.01% 2837

Other funds holding DXCM

Guggenheim Capital's DXCM Position: Q2 2026 in Review

Guggenheim Capital increased its DexCom (DXCM) stake by 34% in Q2 2026, buying an estimated $2.1M and bringing the position to 125,518 shares worth $8.45M. The position accounts for 0.05% of the portfolio, ranked #332.

Guggenheim Capital first reported a position in DXCM in Q4 2013 and has held it in 51 quarters since. The position peaked at $36.7M in Q4 2021. 970 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Guggenheim Capital held 125,518 shares of DexCom worth $8.45M as of Q2 2026.
  • Guggenheim Capital bought 31,550 DexCom shares in Q2 2026, an estimated $2.1M.
  • DexCom made up 0.05% of Guggenheim Capital's portfolio in Q2 2026, its #332 holding.
  • Guggenheim Capital first reported a position in DexCom in Q4 2013 and has held it in 51 quarters since.
  • Guggenheim Capital's DexCom position peaked at $36.7M in Q4 2021.
  • 970 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.